The document provides information about the Biomedical Cluster at Skolkovo Innovation Centre in Russia. It aims to transform Russia's pharmaceutical market into a $31.25 billion industry by 2015 by attracting major medical research companies. The cluster brings together international and Russian scientists, entrepreneurs, and investors to conduct cutting-edge biomedical research commercialize innovations. It has over 90 corporate members including Johnson & Johnson. The goal is to create a global research hub that develops solutions to health challenges and builds an international network of excellence.

1. factsheet_Bio_final:Layout 1 15/01/12 23:27 Page 1
Media Factsheet
kit
02
Biomedical Cluster
Biomedical Factsheet
construction of this dynamic ecosystem of
Russia has more physicians, Russian and international companies, universities
hospitals and health care and public bodies that we can truly achieve our
workers per capita than any vision and form a global innovation hub.
other country in the world, but
both its medical research and
native pharmaceutical market Prof Igor Goryanin is the Executive Director of the
are underdeveloped. The Biomedical cluster. In addition to his role in
Biomedical Cluster is designed Skolkovo, Prof Goryanin holds the Henrik Kacser
to help transform Russia’s Chair in Computational Systems Biology at the
pharmaceutical market into a University of Edinburgh and heads the Laboratory
$31.25 billion industry by 2015 of Biological Systems, at the Okinawa Institute of
Science and Technology (Japan). Prof Goryanin is
by attracting the biggest names well acquainted with working at the global level
in medical research. standards of best practice in leading scientific with international teams, having led several high
centres around the world. profile international collaborations with research
Thus, our cluster will prioritise the following sectors groups across Europe, China, Japan and the USA.
By fostering an ecosystem of excellence around of activity: Prof Goryanin also has the commercial and
biotechnology and medical technology, the entrepreneurial background essential to ensure
• Clinical medicine & healthcare
Skolkovo Innovation Centre’s Biomedical Cluster the cluster’s success, having co-founded and led
has put in motion a process that aspires to build • Biomedical & life sciences
Biobank Inc., Russia.
global market leaders in the life sciences industry. • Bioinformatics, and
This cluster of internationally leading scientists • Industrial biotechnologies
using the latest facilities and techniques will
enable us to produce cutting-edge research that The cluster will not only design and carry out
leads to innovative technologies, instruments and innovative research within these categories, but it
services that will help improve the quality of will also oversee the entire commercialisation
healthcare worldwide. process to transform technology from the labo-
ratory into marketable world class goods and
services.
Russia, as elsewhere in the industrialised world, is
facing the challenge of an ageing population that
is putting increasing pressure on both public The Biomedical Cluster brings leading international
spending and the quality of healthcare – and this and Russian scientists together with entrepreneurs
despite Russia having more physicians, hospitals and venture capital funds. Cluster partners will
and health care workers per capita than any other have at their disposal an array of cutting-edge
country in the world. But Russia’s biomedical equipment, infrastructure and business services.
industry accounts for only 0.2% of the world 90 companies including Johnson & Johnson
market and many Russian companies currently and its pharmaceutical branch Janssen
need to conduct their research abroad. Pharmaceutica and Immunotech Developments
have already joined the cluster which each week
receives additional applications for corporate
participation.
To meet the challenges and reinforce Russia’s
Our cluster is also rapidly developing strategic
global performance in the sector, the Biomedical
partnerships with leading universities and research
Cluster aspires to create a global research hub
institutes around the world. This truly global
in Skolkovo to develop new and innovative
network includes:
solutions to current and future health challenges.
At the same time it seeks to commercialise the • Harvard Medical School
innovations and to build a network/ecosystem of • Tel Aviv University
excellence tapping into expertise from around • Okinawa Institute of Science and Technology
the world.
• King’s College London
To accomplish this mission, the cluster has iden-
tified R&D priorities that not only reflect the We also have strong support from a wide variety of
global context, but also are informed by the public and private partners within the Russian
Federation. The Ministry of Health and Social
Development, the Ministry of Industry and Trade
and the Ministry of Economic Development
00 01 03
Energy
04
Space
05 number among our partners as do major players
For more information: http://www.sk.ru/en/
Skolkovo IT Nuclear
from Russia’s biomedical industry including
02
Biomedical RVC, RUSNANO and EMBL. It is through the
Factsheet
www.sk.ru/en